|
1.
|
Estey EH: Treatment of relapsed and
refractory acute myelogenous leukemia. Leukemia. 14:476–479. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Chen Y, Tang Y, Guo C, Wang J, Boral D and
Nie D: Nuclear receptors in the multidrug resistance through the
regulation of drug-metabolizing enzymes and drug transporters.
Biochem Pharmacol. 83:1112–1126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Nagano H, Tomimaru Y, Eguchi H, et al:
MicroRNA-29a induces resistance to gemcitabine through the
Wnt/beta-catenin signaling pathway in pancreatic cancer cells. Int
J Oncol. 43:1066–1072. 2013.PubMed/NCBI
|
|
6.
|
Croce C: Introduction to the role of
microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J.
18:213–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Feng DD, Zhang H, Zhang P, et al:
Down-regulated miR-331-5p and miR-27a are associated with
chemotherapy resistance and relapse in leukaemia. J Cell Mol Med.
15:2164–2175. 2011. View Article : Google Scholar
|
|
8.
|
Li QJ, Chau J, Ebert PJ, et al: miR-181a
is an intrinsic modulator of T cell sensitivity and selection.
Cell. 129:147–161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
de Yebenes VG, Belver L, Pisano DG, et al:
miR-181b negatively regulates activation-induced cytidine deaminase
in B cells. J Exp Med. 205:2199–2206. 2008.PubMed/NCBI
|
|
10.
|
Wang B, Hsu SH, Majumder S, et al:
TGFbeta-mediated upregulation of hepatic miR-181b promotes
hepatocarcinogenesis by targeting TIMP3. Oncogene. 29:1787–1797.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Bisso A, Faleschini M, Zampa F, et al:
Oncogenic miR-181a/b affect the DNA damage response in aggressive
breast cancer. Cell Cycle. 12:1679–1687. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lu Y, Roy S, Nuovo G, et al:
Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of
tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein
and modulating mitogenic signal. J Biol Chem. 286:42292–42302.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Marton S, Garcia MR, Robello C, et al:
Small RNAs analysis in CLL reveals a deregulation of miRNA
expression and novel miRNA candidates of putative relevance in CLL
pathogenesis. Leukemia. 22:330–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Visone R, Veronese A, Rassenti LZ, et al:
miR-181b is a biomarker of disease progression in chronic
lymphocytic leukemia. Blood. 118:3072–3079. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Li S, Moffett HF, Lu J, et al: MicroRNA
expression profiling identifies activated B cell status in chronic
lymphocytic leukemia cells. PLoS One. 6:e169562011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Visone R, Veronese A, Balatti V and Croce
CM: MiR-181b: new perspective to evaluate disease progression in
chronic lymphocytic leukemia. Oncotarget. 3:195–202.
2012.PubMed/NCBI
|
|
18.
|
Dore LC, Amigo JD, Dos Santos CO, et al: A
GATA-1-regulated microRNA locus essential for erythropoiesis. Proc
Natl Acad Sci USA. 105:3333–3338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Wang R, Wang ZX, Yang JS, Pan X, De W and
Chen LB: MicroRNA-451 functions as a tumor suppressor in human
non-small cell lung cancer by targeting ras-related protein 14
(RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Bian HB, Pan X, Yang JS, Wang ZX and De W:
Upregulation of microRNA-451 increases cisplatin sensitivity of
non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res.
30:202011. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Kovalchuk O, Filkowski J, Meservy J, et
al: Involvement of microRNA-451 in resistance of the MCF-7 breast
cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther.
7:2152–2159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Wang J, Tian X, Han R, et al:
Downregulation of miR-486-5p contributes to tumor progression and
metastasis by targeting protumorigenic ARHGAP5 in lung cancer.
Oncogene. 33:1181–1189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ragusa M, Majorana A, Statello L, et al:
Specific alterations of microRNA transcriptome and global network
structure in colorectal carcinoma after cetuximab treatment. Mol
Cancer Ther. 9:3396–3409. 2010. View Article : Google Scholar
|
|
24.
|
Ji M, Li J, Yu H, et al: Simultaneous
targeting of MCL1 and ABCB1 as a novel strategy to overcome drug
resistance in human leukaemia. Br J Haematol. 145:648–656. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Xiang L, Li M, Liu Y, et al: The clinical
characteristics and prognostic significance of MN1 gene and
MN1-associated microRNA expression in adult patients with de novo
acute myeloid leukemia. Ann Hematol. 92:1063–1069. 2013. View Article : Google Scholar
|
|
26.
|
Li Z, Huang H, Li Y, et al: Up-regulation
of a HOXA-PBX3 homeobox-gene signature following down-regulation of
miR-181 is associated with adverse prognosis in patients with
cytogenetically abnormal AML. Blood. 119:2314–2324. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Garzon R, Garofalo M, Martelli MP, et al:
Distinctive microRNA signature of acute myeloid leukemia bearing
cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA.
105:3945–3950. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Marcucci G, Maharry K, Radmacher MD, et
al: Prognostic significance of, and gene and microRNA expression
signatures associated with, CEBPA mutations in cytogenetically
normal acute myeloid leukemia with high-risk molecular features: a
Cancer and Leukemia Group B Study. J Clin Oncol. 26:5078–5087.
2008. View Article : Google Scholar
|
|
29.
|
Marcucci G, Radmacher MD, Maharry K, et
al: MicroRNA expression in cytogenetically normal acute myeloid
leukemia. N Engl J Med. 358:1919–1928. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Zhi F, Cao X, Xie X, et al: Identification
of circulating microRNAs as potential biomarkers for detecting
acute myeloid leukemia. PLoS One. 8:e567182013. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Li H, Hui L and Xu W: miR-181a sensitizes
a multidrug-resistant leukemia cell line K562/A02 to daunorubicin
by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai).
44:269–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Bai H, Cao Z, Deng C, Zhou L and Wang C:
miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C
by inducing apoptosis. J Cancer Res Clin Oncol. 138:595–602. 2012.
View Article : Google Scholar
|
|
33.
|
Andersson U and Tracey KJ: HMGB1 is a
therapeutic target for sterile inflammation and infection. Annu Rev
Immunol. 29:139–162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Tang D, Kang R, Zeh HJ III and Lotze MT:
High-mobility group box 1 and cancer. Biochim Biophys Acta.
1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Kang R, Tang DL, Cao LZ, Yu Y, Zhang GY
and Xiao XZ: High mobility group box 1 is increased in children
with acute lymphocytic leukemia and stimulates the release of tumor
necrosis factor-alpha in leukemic cell. Zhonghua Er Ke Za Zhi.
45:329–333. 2007.(In Chinese).
|
|
36.
|
Liu L, Yang M, Kang R, et al:
HMGB1-induced autophagy promotes chemotherapy resistance in
leukemia cells. Leukemia. 25:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Xie M, Kang R, Yu Y, et al: Enhancive
effect of HMGB1 gene silence on adriamycin-induced apoptosis in
K562/A02 drug resistance leukemia cells. Zhonghua Xue Ye Xue Za
Zhi. 29:549–552. 2008.(In Chinese).
|
|
38.
|
Kozopas KM, Yang T, Buchan HL, Zhou P and
Craig RW: MCL1, a gene expressed in programmed myeloid cell
differentiation, has sequence similarity to BCL2. Proc Natl Acad
Sci USA. 90:3516–3520. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Placzek WJ, Wei J, Kitada S, Zhai D, Reed
JC and Pellecchia M: A survey of the anti-apoptotic Bcl-2 subfamily
expression in cancer types provides a platform to predict the
efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis.
1:e402010. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Kaufmann SH, Karp JE, Svingen PA, et al:
Elevated expression of the apoptotic regulator Mcl-1 at the time of
leukemic relapse. Blood. 91:991–1000. 1998.PubMed/NCBI
|
|
41.
|
Kasper S, Breitenbuecher F, Heidel F, et
al: Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to
cytotoxic therapies. Blood Cancer J. 2:e602012. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Zhu DX, Zhu W, Fang C, et al: miR-181a/b
significantly enhances drug sensitivity in chronic lymphocytic
leukemia cells via targeting multiple anti-apoptosis genes.
Carcinogenesis. 33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Zhan Z, Li Q, Wu P, et al:
Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric
cancer cells induced by vincristine via transcriptional regulation
of Mcl-1. Autophagy. 8:109–121. 2012. View Article : Google Scholar : PubMed/NCBI
|
